Trials / Completed
CompletedNCT06045299
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Corxel Pharmaceuticals · Industry
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of Presbyopia
Detailed description
A multicenter, randomized, double-masked, placebo-controlled efficacy and safety study . To evaluate the efficacy and safety of LNZ101 (Aceclidine 1.75%/Brimonidine 0.08%)/LNZ100 (Aceclidine 1.75%) compared with placebo for the treatment of presbyopia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aceclidine+Brimonidine combination ophthalmic solution | Aceclidine+Brimonidine combination ophthalmic solution |
| DRUG | Aceclidine ophthalmic solution | Aceclidine ophthalmic solution |
| DRUG | Placebo (Vehicle) ophthalmic solution | Placebo (Vehicle) ophthalmic solution |
Timeline
- Start date
- 2023-09-27
- Primary completion
- 2024-08-19
- Completion
- 2025-01-27
- First posted
- 2023-09-21
- Last updated
- 2025-03-03
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06045299. Inclusion in this directory is not an endorsement.